[1]茹文鑫 周婷 高玉霞.心血管疾病的代谢组学研究进展[J].心血管病学进展,2021,(1):72-75.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
 RU Wenxin,ZHOU Ting,GAO Yuxia.Metabonomics in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2021,(1):72-75.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
点击复制

心血管疾病的代谢组学研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年1期
页码:
72-75
栏目:
综述
出版日期:
2021-01-25

文章信息/Info

Title:
Metabonomics in Cardiovascular Diseases
文章编号:
202006053
作者:
茹文鑫12 周婷 12 高玉霞 2
(1.天津医科大学研究生院,天津300052; 2.天津医科大学总医院心血管内科,天津300052)
Author(s):
RU Wenxin12ZHOU Ting12GAO Yuxia2
(1.Graduate School of Tianjin Medical University,Tianjin 300052 ,China; 2.Department of Cardiovascular Medicine,General Hospital of Tianjin Medical University,Tianjin 300052 ,China)
关键词:
心血管疾病代谢组学代谢标志物
Keywords:
Cardiovascular diseaseMetabolomicsMetabolic marker
DOI:
10.16806/j.cnki.issn.1004-3934.2021.01.000
摘要:
心血管疾病负担日益加重,给国民健康造成巨大威胁。随着代谢组学技术研究的发展和进步,其正成为心血管疾病诊断、治疗及预后评估的一大利器。现就心血管领域的代谢组学研究进展做一简要综述。
Abstract:
The increasing burden of cardiovascular disease poses a great threat to national health. With the development and progress of metabolomics,it is becoming a powerful tool for the diagnosis,treatment and prognosis of cardiovascular diseases. This paper reviews the progress of metabolomics in the cardiovascular field

参考文献/References:

[1]胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J]. 中国循环杂志,201934(3):F209-F220.

[2]Benjamin EJ,Virani SS,Callaway CW,et al. Heart disease and stroke statistics—2018 update:a report from the American Heart Association[J]. Circulation,2018,137(12):e67-e492.

[3] Roberts LD,Gerszten RE. Toward new biomarkers of cardiometabolic diseases[J]. Cell Metab,2013,18(1):43-50.

[4]???Stryeck S,Birner-Gruenberger R,Madl T. Integrative metabolomics as emerging tool to study autophagy regulation[J]. Microb Cell,2017,4(8):240-258.

[5]?Shah SH,Kraus WE,Newgard CB. Mtabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases:form and function[J]. Circulation,2012,126(9):1110-1120.

[6]?Johnson CH,Ivanisevic J,Siuzdak G. Metabolomics:beyond biomarkers and towards mechanisms[J]. Nat Rev Mol Cell Biol,2016,17(7):451-459.

[7]???Paapstel K,Kals J,Eha J,et al. Metabolomic profiles of lipid metabolism,arterial stiffness and hemodynamics in male coronary artery disease patients[J]. IJC Metab Endocr,2016,11:13-18.

[8]?Zhang L,Wei TT,Li Y,et al. Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases[J]. Circulation,2018,137(13): 1374-1390.

[9]???Amin AM,Mostafa H,Arif NH,et al. Metabolomics profiling and pathway analysis of human plasma and urine reveal further insights into the multifactorial nature of coronary artery disease[J]. Clin Chim Acta,2019,493:112-122.

[10]?Ali SE,Farag MA,Holvoet P,et al. A comparative metabolomics approach reveals early biomarkers for metabolic response to acute myocardial infarction[J]. Sci Rep,2016,6:36359.

[11]?Mythili S,Malathi N. Diagnostic markers of acute myocardial infarction[J]. Biomed Rep,2015,3(6):743-748.

[12]?Cheng ML,Wang CH,Shiao MS,et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure:diagnostic and prognostic value of metabolomics[J]. J Am Coll Cardiol,2015,65(15):1509-1520.

[13]?Chacko S,Haseeb S,Glover BM,et al. The role of biomarkers in the diagnosis and risk stratification of acute coronary syndrome[J]. Future Sci OA,2017,4(1):FSO251.

[14]??McGarrah RW,Crown SB,Zhang GF,et al. Cardiovascular metabolomics[J]. Circ Res,2018, 122(9):1238-1258.

[15]??Fan Y,Li Y,Chen Y,et al. Comprehensive metabolomic characterization of coronary artery diseases[J]. J Am Coll Cardiol,2016,68(12):1281-1293.

[16] Ward-Caviness CK,Xu T,Aspelund T,et al. Improvement of myocardial infarction risk prediction via inflammation-associated metabolite biomarkers[J]. Heart,2017,103(16): 1278-1285.

[17]?Floegel A,Kühn T,Sookthai D,et al. Serum metabolites and risk of myocardial infarction and ischemic stroke:a targeted metabolomic approach in two German prospective cohorts[J]. Eur J Epidemiol,2018,33(1):55-66.

[18]?Goulart VAM,Santos AK,Sandrim VC,et al. Metabolic disturbances identified in plasma samples from ST-segment elevation myocardial infarction patients[J]. Dis Markers,2019,7676189.

[19]?Lu J,Chen B,Chen T,et al. Comprehensive metabolomics identified lipid peroxidation as a prominent feature in human plasma of patients with coronary heart diseases[J]. Redox Biol,2017,12:899-907.

[20]?Ussher JR,Elmariah S,Gerszten RE,et al. The Emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease[J]. J Am Coll Cardiol,2016,68(25):2850-2870.

[21] Heggermont WA,Papageorgiou AP,Heymans S,et al. Metabolic support for the heart:complementary therapy for heart failure?[J]. Eur J Heart Fail,2016,18(12):1420-1429.

[22]?Marcinkiewicz-Siemion M,Ciborowski M,Kretowski A,et al. Metabolomics-A wide-open door to personalized treatment in chronic heart failure?[J]. Int J Cardiol,2016,219:156-163.

[23]?Sun H,Olson KC,Gao C,et al. Catabolic defect of branched-chain amino acids promotes heart failure[J]. Circulation,2016,133(21):2038-2049.

[24]??Bedi Jr KC,Snyder NW,Brandimarto J,et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure[J]. Circulation,2016,133(8):706-716.

[25]?Ahmad T,Kelly JP,McGarrah RW,et al. Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support[J]. J Am Coll Cardiol,2016,67(3):291-299.

[26]?Lanfear DE,Gibbs JJ,Li J,et al. Targeted metabolomic profiling of plasma and survival in heart failure patients[J]. JACC Heart Fail,2017,5(11):823-832.

[27]?Evans RD,Hauton D. The role of triacylglycerol in cardiac energy provision[J]. Biochim Biophys Acta,2016,1861(10):1481-1491.

[28]?Dunlay SM,Roger VL,Redfield MM. Epidemiology of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol,2017,14(10):591-602.

[29] Lee CH,Hung KC,Chang SH,et al. Reversible left ventricular diastolic dysfunction on Doppler tissue imaging predicts a more favorable prognosis in chronic heart failure[J]. Circ J, 2012,76(5):1145-1150.

[30]?Razavi AC,Bazzano LA,He J,et al. Novel findings from a metabolomics study of left ventricular diastolic function:The Bogalusa Heart Study[J]. J Am Heart Assoc,2020,9(3): e015118.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
 BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
 REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(1):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
 YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
 ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
 QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
 JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
 HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(1):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
 Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
 WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(1):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
[11]王清腾 金映筑 罗振华 李伟.代谢组学在冠心病中的研究进展[J].心血管病学进展,2021,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
 WANG Qingteng JIN Yingzhu LUO Zhenhua LI Wei.Metabolomics in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2021,(1):812.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]

更新日期/Last Update: 2021-03-18